Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1–2 trialsAlexander Drilon, Robert C. Doebele, Matthew Krebs et al.|The Lancet Oncology|2019Cited by 537
Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 studyShubham Pant, Christophe Le Tourneau, Martin Schüler et al.|The Lancet Oncology|2023Cited by 195